Market Research Logo

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2016

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2016’, provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Stargardt Disease)
    • The report reviews pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Juvenile Macular Degeneration (Stargardt Disease) therapeutics and enlists all their major and minor projects
    • The report assesses Juvenile Macular Degeneration (Stargardt Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease)
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease)
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Juvenile Macular Degeneration (Stargardt Disease) pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Juvenile Macular Degeneration (Stargardt Disease) Overview
    Therapeutics Development
    Pipeline Products for Juvenile Macular Degeneration (Stargardt Disease) - Overview
    Pipeline Products for Juvenile Macular Degeneration (Stargardt Disease) - Comparative Analysis
    Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics under Development by Companies
    Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics under Investigation by Universities/Institutes
    Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Products Glance
    Clinical Stage Products
    Early Stage Products
    Juvenile Macular Degeneration (Stargardt Disease) - Products under Development by Companies
    Juvenile Macular Degeneration (Stargardt Disease) - Products under Investigation by Universities/Institutes
    Juvenile Macular Degeneration (Stargardt Disease) - Companies Involved in Therapeutics Development
    Acucela Inc.
    Alkeus Pharmaceuticals, Inc.
    Astellas Pharma Inc.
    Copernicus Therapeutics, Inc.
    Iris Pharma
    Sanofi
    Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    ALK-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    echothiophate iodide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    emixustat hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy 1 to Activate ABCA4 for Stargardt Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MA09-hRPE - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Oligonucleotides to Activate ABCA4 for Stargardt Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ramiprilat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SAR-422459 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    soraprazan - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Ophthalmic Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VM-200 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects
    Juvenile Macular Degeneration (Stargardt Disease) - Product Development Milestones
    Featured News & Press Releases
    May 26, 2015: Ocata Therapeutics Receives Three New U.S. Patents for its RPE Therapy for Macular Degenerative Diseases
    May 04, 2015: European Medicines Agency Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease
    Mar 31, 2015: Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies
    Oct 15, 2014: ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration
    Sep 25, 2014: Advanced Cell Technology Announces Final Patient Treated in Stargardt’s Macular Degeneration Phase 1 Trial in the United Kingdom
    Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials
    May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells
    Apr 23, 2013: ACT Initiates Higher-Dosage Patient Treatment In European Phase I Study For Macular Degeneration
    Apr 15, 2013: ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt’s Macular Dystrophy
    Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy
    Mar 14, 2013: Advanced Cell Technology Receives DSMB Approval To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials Using hESC-derived RPE Cells
    Jan 08, 2013: Advanced Cell Technology Achieves Clinical Milestone
    Dec 17, 2012: ACT Completes Higher-Dosage Cohort In European Clinical Trial For Stargardt's Macular Dystrophy Using Retinal Pigment Epithelial Cells
    Nov 28, 2012: ACT Completes Higher-Dosage Cohort In Both US Clinical Trials Using Retinal Pigment Epithelial Cells
    Nov 08, 2012: Advanced Cell Technology Announces Interim Data From Three Ongoing Macular Degeneration Trials
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H2 2016
    Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Acucela Inc., H2 2016
    Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alkeus Pharmaceuticals, Inc., H2 2016
    Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Astellas Pharma Inc., H2 2016
    Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Copernicus Therapeutics, Inc., H2 2016
    Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Iris Pharma, H2 2016
    Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Sanofi, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects, H2 2016
    List of Figures
    Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H2 2016
    Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report